Form 4 Tracker
Dyne Therapeutics, Inc.
DYN

46 insider filings · Latest: Jul 27, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Aug 14, 2026Aug 14 9:47 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
322,465$25.96$8.4M

View →

Aug 14, 2026Aug 14 9:47 PMAtlas Venture Fund XI, LP
Proposed Sale
1,359,674$25.96$35.3M

View →

Aug 14, 2026Aug 14 9:46 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
478,377$25.96$12.4M

View →

Aug 13, 2026Aug 13 9:36 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
94,415$26.17$2.5M

View →

Aug 13, 2026Aug 13 9:36 PMAtlas Venture Fund XI, LP
Proposed Sale
268,354$26.17$7.0M

View →

Aug 13, 2026Aug 13 9:36 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
63,643$26.17$1.7M

View →

Aug 13, 2026Aug 13 9:04 PMCox John
Proposed Sale
4,986$26.28$131.0K

View →

Aug 13, 2026Aug 13 9:03 PMLucera Erick
Proposed Sale
1,797$26.28$47.2K

View →

Aug 13, 2026Aug 13 9:03 PMKerr Douglas
Proposed Sale
2,443$26.28$64.2K

View →

Jul 27, 2026Jul 29 8:15 PMDirk KerstenDirector
Sale
261,460$25.51$6.7M3,586,796(I)

View →

Jul 27, 2026Jul 27 8:19 PMForDyne B.V.
Proposed Sale
261,460$25.51$6.7M

View →

Jul 7, 2026Jul 8 9:35 PMJason P RhodesDirector
Sale
297,211$23.26$6.9M2,962(I)

View →

Jul 6, 2026Jul 8 9:35 PMJason P RhodesDirector
Sale
480,240$22.79$10.9M875,912(I)

View →

Jul 7, 2026Jul 7 9:06 PMATLAS VENTURE ASSOCIATES XI, L.P.
Proposed Sale
5,000$22.84$114.2K

View →

Jul 7, 2026Jul 7 9:06 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
60,858$22.84$1.4M

View →

Jul 7, 2026Jul 7 9:05 PMAtlas Venture Fund XI, LP
Proposed Sale
153,966$22.84$3.5M

View →

Jul 7, 2026Jul 7 9:05 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
77,387$22.84$1.8M

View →

Jul 6, 2026Jul 6 9:17 PMAtlas Venture Opportunity Fund I, LP
Proposed Sale
100,019$23.07$2.3M

View →

Jul 6, 2026Jul 6 9:17 PMAtlas Venture Fund XI, LP
Proposed Sale
253,039$23.07$5.8M

View →

Jul 6, 2026Jul 6 9:17 PMAtlas Venture Opportunity Fund II, LP
Proposed Sale
127,182$23.07$2.9M

View →

Page 1 of 9

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 22, 2026Jun 23 8:07 PMBarry E GreeneDirector
Grant/Award
57,463$20.8757,463(D)

View →

Jun 5, 2026Jun 9 9:15 PMEdward HurwitzDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:13 PMDavid Charles LubnerDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:13 PMJason P RhodesDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:12 PMDirk KerstenDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:12 PMCarlo IncertiDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:09 PMCatherine Stehman-BreenDirector
Grant/Award
35,152$17.0435,152(D)

View →

Jun 5, 2026Jun 9 9:06 PMBrian S PosnerDirector
Grant/Award
35,152$17.0435,152(D)

View →

Feb 12, 2026Feb 17 10:11 PMJohn CoxDirector, CEO & President
Grant/Award
285,000$16.00285,000(D)

View →

Feb 12, 2026Feb 17 10:10 PMDouglas KerrChief Medical Officer
Grant/Award
130,000$16.00130,000(D)

View →

Feb 12, 2026Feb 17 10:09 PMJohanna Friedl-NadererChief Commercial Officer
Grant/Award
90,000$16.0090,000(D)

View →

Feb 12, 2026Feb 17 10:08 PMErick LuceraChief Financial Officer
Grant/Award
105,000$16.00105,000(D)

View →